Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:AIR
NYSE:AIRAerospace & Defense

AAR Corp (AIR) Margin Recovery In Q2 2026 Reinforces Bullish Profitability Narratives

AAR Corp. (AIR) has reported results for Q2 2026, with revenue of US$795.3 million and basic EPS of US$0.92, alongside trailing twelve month EPS of US$2.59 and net income of US$94.1 million. The company’s revenue has increased from US$686.1 million in Q2 2025 to US$795.3 million in Q2 2026, while quarterly EPS has moved from a loss of US$0.87 to a profit of US$0.92. This represents a very large year-over-year earnings improvement that feeds into forecasts calling for about 34.7% annual...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Is Protagonist Therapeutics (PTGX) Still Attractive After Recent Share Price Volatility

Wondering whether Protagonist Therapeutics at around US$82 per share is still offering value, or if the best part of the opportunity has passed? This article is aimed at helping you frame that question clearly. The stock has been volatile in the short term, with a 5.8% decline over the last week and an 8.9% decline over the last month, even though the 1 year return stands at 118.6% and the 5 year return at 285.6%. These sharp moves come against a backdrop of ongoing interest in Protagonist...
NasdaqGS:INDV
NasdaqGS:INDVPharmaceuticals

Is Indivior (INDV) Still Attractive After A 197% One Year Share Price Surge

If you are wondering whether Indivior at around US$35.89 still offers value after a strong run, this article will walk through what the current price might be implying about the company. The stock has delivered a 196.9% return over the last year and a 414.6% return over five years, although the last 30 days saw a 1.9% decline and the last week was flat. Investors have been reacting to ongoing news flow around the company and its position in the pharmaceutical and biotech space, which...